Umbilical cord blood transplantation in adults with advanced hodgkin's disease: high incidence of post-transplant lymphoproliferative disease-Reference-Cited by-同舟云学术

Umbilical cord blood transplantation in adults with advanced hodgkin's disease: high incidence of post-transplant lymphoproliferative disease

Published:2015-04-18 Issue:2 Volume:96 Page:128-135
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Piñana José Luis¹,Sanz Jaime²,Esquirol Albert³,Martino Rodrigo³,Picardi Alessandra⁴,Barba Pere⁵,Parody Rocio⁶,Gayoso Jorge⁷,Montesinos Pau²,Guidi Stefano⁸,Terol Maria José¹,Moscardó Federico²,Solano Carlos¹,Arcese William⁴,Sanz Miguel A.²⁹,Sierra Jorge³¹⁰,Sanz Guillermo²,

Affiliation:

1. Department of Hematology; Hospital Clínico Universitario; Fundación INCLIVA; Valencia Spain

2. Department of Hematology; Hospital Universitario La Fe; Valencia Spain

3. Department of Hematology; Hospital de la Santa Creu i Sant Pau; Barcelona Spain

4. Rome Transplant Network; UOC Trapianto di Cellule Staminali; Università di Roma Tor Vergata; Rome Italy

5. Department of Hematology; Hospital Universitari Vall D'Hebron; Barcelona Spain

6. Department of Clinical Hematology; Hospital Virgen del Rocio; Sevilla Spain

7. Department of Hematology; Hospital Gregorio Marañon; Madrid Spain

8. Bone Marrow Transplant Unit; Department of Hematology; AOU Careggi; Florence Italy

9. Medicine Department; Universitat de Valencia; Valencia Spain

10. Hospital de la Santa Creu i Sant Pau; IIB Sant Pau and Jose Carreras Leukemia Research Institute; Universidad Autónoma de Barcelona; Barcelona Spain

Funder

Instituto de Salud Carlos III

Fundación Cellex

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ejh.12557/fullpdf

Reference37 articles.

1. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas;Younes;N Engl J Med,2010

2. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma;Younes;J Clin Oncol,2012